BioLife Solutions, Inc. Fundamental Analysis (NASDAQ: BLFS)
BioLife Solutions, Inc. Fundamental Analysis (NASDAQ: BLFS)
BioLife Solutions, Inc. (NASDAQ: BLFS) shows moderate financial fundamentals with a PE ratio of 35.82, profit margin of 49.06%, and ROE of 13.29%. The company generates $0.1B in annual revenue with strong year-over-year growth of 16.97%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 74.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BLFS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBLFS demonstrates superior asset utilization.
Valuation Score
ModerateBLFS shows balanced valuation metrics.
Growth Score
ExcellentBLFS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBLFS maintains a strong and stable balance sheet.
Profitability Score
WeakBLFS struggles to sustain strong margins.
Key Financial Metrics
Is BLFS Expensive or Cheap?
P/E Ratio
BLFS trades at 35.82 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BLFS's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values BioLife Solutions, Inc. at 4.31 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 185.85 times EBITDA. This signals the market has high growth expectations.
How Well Does BLFS Make Money?
Net Profit Margin
For every $100 in sales, BioLife Solutions, Inc. keeps $49.06 as profit after all expenses.
Operating Margin
Core operations generate 7.25 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.29 in profit for every $100 of shareholder equity.
ROA
BioLife Solutions, Inc. generates $11.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioLife Solutions, Inc. produces operating cash flow of $16.87M, showing steady but balanced cash generation.
Free Cash Flow
BioLife Solutions, Inc. generates weak or negative free cash flow of $-903.83K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
BLFS converts -0.05% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
35.82
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.31
vs 25 benchmark
P/S Ratio
Price to sales ratio
17.60
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.69
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How BLFS Stacks Against Its Sector Peers
| Metric | BLFS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 35.82 | 31.19 | Worse (Expensive) |
| ROE | 13.29% | 447.00% | Weak |
| Net Margin | 49.06% | 21601.00% | Weak |
| Debt/Equity | 0.04 | 0.54 | Strong (Low Leverage) |
| Current Ratio | 9.69 | 5.66 | Strong Liquidity |
| ROA | 11.27% | -50.00% (disorted) | Strong |
BLFS outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioLife Solutions, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
14.41%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-360.07%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
76.55%
Industry Style: Defensive, Growth, Innovation
High Growth